Alpha Teknova (NASDAQ:TKNO) PT Lowered to $12.00

Alpha Teknova (NASDAQ:TKNOGet Rating) had its price target dropped by analysts at Stephens to $12.00 in a research report issued on Wednesday, Stock Target Advisor reports. Stephens’ target price suggests a potential upside of 125.56% from the stock’s current price.

TKNO has been the topic of several other research reports. Cowen lowered their price objective on Alpha Teknova from $13.00 to $8.00 in a research report on Thursday, November 10th. Cowen decreased their target price on shares of Alpha Teknova from $13.00 to $8.00 in a report on Thursday, November 10th.

Alpha Teknova Stock Down 2.6 %

TKNO stock opened at $5.32 on Wednesday. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.68 and a quick ratio of 6.10. The stock has a market capitalization of $149.44 million, a price-to-earnings ratio of -3.94 and a beta of 0.40. The business’s fifty day moving average price is $4.00 and its two-hundred day moving average price is $6.27. Alpha Teknova has a fifty-two week low of $3.02 and a fifty-two week high of $25.76.

Insider Activity

In other news, Director J Matthew Mackowski bought 10,000 shares of the company’s stock in a transaction dated Wednesday, August 24th. The stock was bought at an average cost of $4.97 per share, for a total transaction of $49,700.00. Following the transaction, the director now owns 5,000 shares of the company’s stock, valued at $24,850. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last ninety days, insiders bought 13,762 shares of company stock worth $65,613. 15.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Alpha Teknova

Hedge funds and other institutional investors have recently made changes to their positions in the company. Conestoga Capital Advisors LLC raised its position in shares of Alpha Teknova by 20.2% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 105,949 shares of the company’s stock valued at $890,000 after buying an additional 17,839 shares in the last quarter. Nicholas Investment Partners LP increased its position in Alpha Teknova by 11.8% during the 1st quarter. Nicholas Investment Partners LP now owns 720,524 shares of the company’s stock worth $9,950,000 after purchasing an additional 76,139 shares in the last quarter. Parkman Healthcare Partners LLC increased its position in Alpha Teknova by 13.6% during the 1st quarter. Parkman Healthcare Partners LLC now owns 119,468 shares of the company’s stock worth $1,650,000 after purchasing an additional 14,260 shares in the last quarter. Grandeur Peak Global Advisors LLC increased its position in Alpha Teknova by 2.9% during the 1st quarter. Grandeur Peak Global Advisors LLC now owns 227,170 shares of the company’s stock worth $3,137,000 after purchasing an additional 6,304 shares in the last quarter. Finally, Platinum Investment Management Ltd. increased its position in Alpha Teknova by 40.8% during the 3rd quarter. Platinum Investment Management Ltd. now owns 337,391 shares of the company’s stock worth $1,127,000 after purchasing an additional 97,797 shares in the last quarter. 24.59% of the stock is currently owned by institutional investors and hedge funds.

Alpha Teknova Company Profile

(Get Rating)

Alpha Teknova, Inc provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.

Featured Articles

Stock Target Advisor logo

Receive News & Ratings for Alpha Teknova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Teknova and related companies with MarketBeat.com's FREE daily email newsletter.